Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection

Annals of Internal Medicine

Volumn 137, Issue 12, 2002, Pages 961-964

  Alberti, Alfredo ^a   Noventa, Franco ^b   Benvegnù, Luisa ^b   Boccato, Silvia ^b   Gatta, Angelo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; DISEASE SEVERITY; EMPLOYEE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; VIREMIA;

EID: 0037126675     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-12-200212170-00009     Document Type: Article

References (20)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis. 2000;20:1-16. [PMID: 10895428]
2. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82. [PMID: 10706572]
3. Deuffic S, Buffar L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999;29:1596-601. [PMID: 10216148]
4. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol. 1999;31 Suppl 1:17-24. [PMID: 10622555]
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINMR, and DOSVIRC groups. Lancet. 1997;349:825-32. [PMID: 9121257]
6. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26:485-90. [PMID: 9252163]
7. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730-5. [PMID: 9620350]
8. Pagliaro L, Peri V, Linea C, Cammà C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol. 1999;31:28-44. [PMID: 10091101]
9. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: Detection and significance. Semin Liver Dis. 2000;20:47-55. [PMID: 10895431]
10. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196-200. [PMID: 11124836]
11. Hirsch KR, Wright TL. The dilemma of disease progression in hepatitis C patients with normal serum aminotransferase levels [Editorial]. Am J Med. 2000; 109:66-7. [PMID: 10936482]
12. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C in asymptomatic blood donors. Hepatology. 1997;26:29S-33S. [PMID: 9305660]
13. Esteban JI, López-Talavera JC, Genescà J, Madoz P, Viladomiu L, Muñiz E, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med. 1991; 115:443-9. [PMID: 1651674]
14. Alberti A, Chemello L, Cavalletto D, Tagger A, Dal Canton A, Bizzaro N, et al. Antibody to hepatitis C virus and liver disease in volunteer blood donors, Ann Intern Med. 1991;114:1010-2. [PMID: 1851402]
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24: 289-93. [PMID: 8690394]
16. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol. 1999;31 Suppl 1:3-8. [PMID: 10622553]
17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-65. [PMID: 11583749]
18. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998;27:868-72. [PMID: 9500720]
19. Persico M, Persico E, Suozzo R, Conte S, De Sera M, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000; 118:760-4. [PMID: 10734027]
20. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet. 1992;340:697-8. [PMID: 1355801]